Top-News

Precigen Aktie News

Aktie
WKN:  A2PZG1 ISIN:  US74017N1054 US-Symbol:  PGEN Branche:  Biotechnologie Land:  USA
3,192 €
-0,026 €
-0,81%
07:30:38 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,23 Mrd. €
Streubesitz
23,36%
KGV
-2,60
Index-Zuordnung
-

Precigen News

13.11.25 - PR Newswire
Precigen Reports Third Quarter 2025 Financial Results and Business Updates
Precigen Reports Third Quarter 2025 Financial Results and Business Updates PR Newswire
06.11.25 - PR Newswire
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 PR Newswire
13.10.25 - PR Newswire
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-​approved ...
03.09.25 - PR Newswire
Precigen Announces Up to $125 Million Non-Dilutive Financing
Precigen Announces Up to $125 Million Non-​Dilutive Financing PR Newswire
25.08.25 - PR Newswire
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright PR Newswire
15.08.25 - PR Newswire
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-​drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory ...
14.05.25 - PR Newswire
Precigen Reports First Quarter 2025 Financial Results and Business Updates
Precigen Reports First Quarter 2025 Financial Results and Business Updates PR Newswire
19.03.25 - PR Newswire
Precigen Reports Full Year 2024 Financial Results and Business Updates
Precigen Reports Full Year 2024 Financial Results and Business Updates PR Newswire
13.03.25 - PR Newswire
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th PR Newswire
25.02.25 - PR Newswire
FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025
FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, ...
13.01.25 - PR Newswire
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire
09.01.25 - PR Newswire
Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire
30.12.24 - PR Newswire
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis PR Newswire

Newssuche

Videos

newspaper
02.12.25 +8,18%
Technical Trading: DAX Long dienstags
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »